Crohn's Disease

Anti-MAP Therapy Beneficial in Phase 3 Crohn's Disease Trial

By August 01, 2018

The randomized, double-blind, placebo-controlled study (N=331) achieved its primary endpoint and key secondary endpoints in the intent-to-treat (ITT) population.

Biologic Therapies Compared in Patients With Moderate-to-Severe Crohn's Disease

By June 20, 2018

For this study, researchers identified randomized controlled trials that included adults with moderate-to-severe CD treated with various biologic agents (i.e., infliximab, adalimumab, certolizumab pegol, vedolizumab, ustekinumab) as first- or second-line therapies compared with placebo or an active comparator.

Stelara Linked to Reduced Rates of Hospitalization, Surgery in Crohn's Disease

By June 04, 2018

The new analysis pooled patients from the UNITI-1 and UNITI-2 trials who had clinical response after a single intravenous (IV) dose of ustekinumab and entered a 5-year follow-up period.

Cimzia Label Update Provides New Information for Women of Childbearing Age

By March 22, 2018

Data added to the labeling includes first-of-their-kind pharmacokinetic studies demonstrating negligible to low transfer of CIMZIA through placenta and minimal transfer to breast milk from mother to infant.

Limited Data on Combination Biologic Therapy for IBD, Says Study

By February 28, 2018

The authors point out how, unlike other autoinflammatory conditions, "IBD has the benefit of effective and safe gut specific anti-integrin therapies which can provide a platform off of which combinations can be employed."

Biosimilar Ixifi Gets FDA Approval for All Remicade Indications

By December 14, 2017

Ixifi is a chimeric human-murine monoclonal antibody (mAb) against tumor necrosis factor.

Treatment for Fistulizing Crohn's Disease Gets Orphan Drug Status

By October 24, 2017

Cx601 is a first-in-class allogeneic cell therapy intended for patients who have had an inadequate response to at least one conventional or biologic therapy.

Impact of Early Azathioprine Use on Crohn's Disease Progression Evaluated

October 02, 2017

Prior bowel resection, smoking, and low hemoglobin tied to Crohn's-related surgery

Biosimilar Cyltezo Gets FDA Approval for Multiple Indications

By August 28, 2017

This marks the second approval of a biosimilar for adalimumab.

Ustekinumab May Benefit Crohn's Patients Unresponsive to TNFIs

November 18, 2016

Medication potentially helpful in those for whom other treatments haven't worked